Source: PR Newswire
Boehringer Ingelheim, a leader in animal health, inaugurated a state-of-the-art laboratory at its St. Joseph, Mo. location on May 3, 2024. This innovative late-stage R&D lab, unique in the U.S., aims to streamline the transition of products from development to manufacturing, enhancing efficiency and removing operational hurdles. The lab’s flexible design and proprietary equipment will significantly boost the development of future biotherapeutics.
Caroline Belmont, VP of U.S. Global Innovation at Boehringer, emphasized the facility’s pivotal role in driving R&D. The St. Joseph site is essential to Boehringer’s global operations, focusing on livestock and equine health products. The new lab reaffirms Boehringer’s commitment to leading vaccine development and manufacturing. Kim Young, President of KC Animal Health Corridor, highlighted Boehringer’s integral role in the community and industry. Belmont noted the strategic importance of the Midwest location, leveraging local agricultural resources to advance global animal health.